Emancipated' biotechs offer new drugs for neurodegeneration
Article Abstract:
Six new drugs for the rare neurodegenerative disease amyotropic lateral sclerosis (ALS) are poised to enter clinical traits. Of those, two drugs ritonavir and hydroxyurea are products of a tiny, young nonprofit biotechnology company. Nonprofit biotechs focus on accelerating drug discovery for rare or poorly understood diseases, traditionally deemed financially unattractive by large pharmaceutical companies.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Spirituality's rising role in medicine stirs debate
Article Abstract:
Scientists believe that a subjective concept like spirituality cannot and should not be linked to science. Researchers have struggled to differentiate between the health effects of faith and other variables such as behavioral risk factors and socioeconomic issues.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Technologies that deliver
Article Abstract:
Scientist are roiling new ways to deliver a drug directly to its target. But there are many stakes because a therapeutic agent often thwarts disease only when it is delivered actually.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration . Polyglutamine neurodegeneration: minding your Ps and Qs
- Abstracts: A prion protein epitope selective for the pathologically misfolded conformation. The controversial protein-only hypothesis of prion propagation
- Abstracts: Paul Epstein. Paging all doctors. Kari Stefansson